NZ628969A - Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme - Google Patents

Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Info

Publication number
NZ628969A
NZ628969A NZ628969A NZ62896913A NZ628969A NZ 628969 A NZ628969 A NZ 628969A NZ 628969 A NZ628969 A NZ 628969A NZ 62896913 A NZ62896913 A NZ 62896913A NZ 628969 A NZ628969 A NZ 628969A
Authority
NZ
New Zealand
Prior art keywords
pyrimidin
pyrazolo
methyl sulfamate
ylamino
dihydroxy
Prior art date
Application number
NZ628969A
Other languages
English (en)
Inventor
Roushan Afroze
Indu T Bharathan
Jeffrey P Ciavarri
Paul E Fleming
Jeffrey L Gaulin
Mario Girard
Steven P Langston
Francois R Soucy
Tzu-Tshin Wong
Yingchun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ628969A publication Critical patent/NZ628969A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ628969A 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme NZ628969A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
PCT/US2013/026113 WO2013123169A1 (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Publications (1)

Publication Number Publication Date
NZ628969A true NZ628969A (en) 2017-03-31

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628969A NZ628969A (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Country Status (30)

Country Link
US (4) US9290500B2 (enExample)
EP (3) EP3173413B1 (enExample)
JP (1) JP6122877B2 (enExample)
KR (1) KR20140123104A (enExample)
CN (1) CN104136399B (enExample)
AR (1) AR092797A1 (enExample)
BR (1) BR112014020365B1 (enExample)
CA (1) CA2864672C (enExample)
CL (1) CL2014002181A1 (enExample)
CO (1) CO7071135A2 (enExample)
CR (1) CR20140380A (enExample)
DO (1) DOP2014000187A (enExample)
EA (1) EA035020B1 (enExample)
EC (1) ECSP14019113A (enExample)
ES (1) ES2739150T3 (enExample)
GE (1) GEP201706687B (enExample)
HK (1) HK1201817A1 (enExample)
IL (1) IL234016A0 (enExample)
MA (1) MA35932B1 (enExample)
MX (1) MX352963B (enExample)
NZ (1) NZ628969A (enExample)
PE (1) PE20142244A1 (enExample)
PH (1) PH12014501832A1 (enExample)
SG (2) SG10201606581RA (enExample)
TN (1) TN2014000351A1 (enExample)
TW (1) TWI593688B (enExample)
UA (1) UA116534C2 (enExample)
UY (1) UY34629A (enExample)
WO (1) WO2013123169A1 (enExample)
ZA (1) ZA201406103B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
WO2013123169A1 (en) 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ, インコーポレイテッド Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP6697453B2 (ja) * 2014-10-29 2020-05-20 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ユビキチン活性化酵素阻害物質及び放射線の投与
WO2016069392A1 (en) 2014-10-29 2016-05-06 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
JP7385658B2 (ja) 2018-10-30 2023-11-22 クロノス バイオ インコーポレイテッド Cdk9活性を調節するための化合物、組成物、および方法
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
MXPA05002573A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002572A (es) 2002-09-04 2005-09-08 Schering Corp Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina.
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
US7642266B2 (en) 2005-10-06 2010-01-05 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
PT1989206E (pt) * 2006-02-02 2012-10-15 Millennium Pharm Inc Inibidores da enzima de ativação e1
EP1992008A1 (en) * 2006-02-28 2008-11-19 Sez Ag Device and method for liquid treating disc-like articles
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
BRPI0715176A8 (pt) * 2006-08-08 2018-04-10 Millennium Pharm Inc compostos de heteroarila utéis como inibidores de enzimas de ativação e1
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
RU2553476C2 (ru) 2007-08-02 2015-06-20 Миллениум Фармасьютикалз, Инк. Способ синтеза ингибиторов е1-активирующего фермента
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG175929A1 (en) * 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
CN103889988B (zh) 2011-08-24 2018-05-04 米伦纽姆医药公司 Nedd8-活化酶的抑制剂
WO2013123169A1 (en) 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ, インコーポレイテッド Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Also Published As

Publication number Publication date
US20140088096A9 (en) 2014-03-27
EA035020B1 (ru) 2020-04-17
EA201400831A1 (ru) 2014-12-30
SG10201606581RA (en) 2016-09-29
EP2814791A4 (en) 2015-08-19
EP3173413A1 (en) 2017-05-31
SG11201404757WA (en) 2014-09-26
MX352963B (es) 2017-12-15
US20170217968A1 (en) 2017-08-03
CL2014002181A1 (es) 2014-12-12
BR112014020365A2 (pt) 2020-12-22
AR092797A1 (es) 2015-05-06
US20130217682A1 (en) 2013-08-22
ZA201406103B (en) 2017-11-29
EP3536692B1 (en) 2021-04-07
HK1201817A1 (en) 2015-09-11
CN104136399B (zh) 2018-08-07
CN104136399A (zh) 2014-11-05
GEP201706687B (en) 2017-06-26
TN2014000351A1 (en) 2015-12-21
KR20140123104A (ko) 2014-10-21
ES2739150T3 (es) 2020-01-29
TWI593688B (zh) 2017-08-01
JP2015508775A (ja) 2015-03-23
EP2814791A1 (en) 2014-12-24
US9796725B2 (en) 2017-10-24
EP3173413B1 (en) 2019-05-01
CR20140380A (es) 2014-10-28
US10202389B2 (en) 2019-02-12
EP3536692A1 (en) 2019-09-11
CA2864672A1 (en) 2013-08-22
MX2014009944A (es) 2014-11-10
PE20142244A1 (es) 2015-01-07
US20170369499A1 (en) 2017-12-28
ECSP14019113A (es) 2015-09-30
UA116534C2 (uk) 2018-04-10
US9290500B2 (en) 2016-03-22
DOP2014000187A (es) 2014-10-15
UY34629A (es) 2013-09-02
US9663525B2 (en) 2017-05-30
TW201345909A (zh) 2013-11-16
MA35932B1 (fr) 2014-12-01
CO7071135A2 (es) 2014-09-30
PH12014501832A1 (en) 2014-11-17
US20160244455A1 (en) 2016-08-25
IL234016A0 (en) 2014-09-30
WO2013123169A1 (en) 2013-08-22
CA2864672C (en) 2018-01-09
JP6122877B2 (ja) 2017-04-26
BR112014020365B1 (pt) 2023-02-23

Similar Documents

Publication Publication Date Title
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
PH12012500690A1 (en) Positive allosteric modulators (pam)
JP2014051526A5 (enExample)
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
GEP20125621B (en) 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
NZ717119A (en) Aryl-or heteroaryl-substituted benzene compounds
PE20110575A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
JP2015500842A5 (enExample)
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
PH12016500427A1 (en) Ethynyl derivatives
PH12012500867A1 (en) Ethynyl derivatives
PH12013501572A1 (en) 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
PE20211776A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
PH12016501481A1 (en) Ethynyl derivatives
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
MX2021014319A (es) Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo.
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500261A1 (en) Arylethynyl pyrimidines
PE20150341A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 FEB 2020 BY HENRY HUGHES IP LIMITED

Effective date: 20171009

LAPS Patent lapsed